Heart valve repair patients: which blood thinner is safest?

NCT ID NCT06901466

Recruiting now Disease control Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at 880 people who had a minimally invasive heart valve repair and also need long-term blood thinners. It compares taking just one blood thinner (rivaroxaban) versus taking two (rivaroxaban plus clopidogrel) to see which causes fewer bleeding problems over one year. The goal is to find the safest option for these patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rivaroxaban and Clopidogrel (blood thinners)
What this could lead to: If it works, this could identify the safest blood thinner regimen after heart valve repair, reducing bleeding risks while preventing clots.
What could go wrong: This is a Phase 4 trial, so the drugs are already approved, but the best strategy is unknown. Bleeding complications remain a risk, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MITRAL REGURGITATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Embolism and Thrombosis Hemorrhage mitral valve insufficiency myocardial infarction stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MITRAL REGURGITATION

Contacts and locations

Locations

Chinese Academy of Medical Sciences, Fuwai Hospital
RECRUITING

Beijing, Beijing Municipality, 100037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.